- Valeant Pharmaceuticals International stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
Valeant Pharmaceuticals International stock price, VRX
Valeant Pharmaceuticals International stock chart:
Valeant Pharmaceuticals International close price: 10.75
Stock price forecast:
UP TO +12.65%
Total forecasts: 90
Reached: 52 (57.78%)
Total Win: 48.13 (327.63%)
Showing 1-10 of 498 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Valeant Pharmaceuticals International latest news:
Ackman's Pershing Square sells Valeant stake, takes $3 billion loss
BOSTON (Reuters) - Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc on Monday with a loss of more than $3 billion as he sold his entire stake in the...
Ackman's Pershing Square exits ailing investment in Valeant
BOSTON (Reuters) - Billionaire investor William Ackman, who had been Valeant Pharmaceuticals International's biggest cheerleader for two years as the share price climbed and then plummeted, on Monday said his hedge fund had sold its entire position.
Valeant sinks on media report Bill Ackman sold stake
Shares of Valeant Pharmaceuticals International Inc. (VRX) sank in Monday's extended session following a CNBC report that hedge fund manager Bill Ackman has sold his stake in the company and plans to step down from the board. Ackman had steadfastedly expressed support for the drug company even after the company's stock plunged in the aftermath of an accounting scandal. Ackman's Pershing Square Capital owned 2.88 million shares, or 9.96% of the company, at the end of 2016. Valeant...
Valeant shares, bonds slump after it says it will seek to amend more of its debt covenants
Valeant Pharmaceuticals International Inc. shares slid 6% Tuesday, after the company said it is seeking to refinance and amend more of its debt, including removing covenants from Term B loans. The company said it will use the proceeds of the sale of its skincare assets to L'Oreal to pay down about $1.1 billion of senior secured term loans. The troubled drug company will seek to refinance and amend its existing credit agreement, issue new Term B loans that extend the maturity of current Term B loans due before 2022, issue new secured debt, and repay its remaining Term A loan due in April 2020. Valeant further plans to repay a portion of its 6.75% secured debt due in 2018, as well as relax maintenance covenants in the revolver and remove the covenants from Term B loans. "While the refinancing is not surprising, it reflects the cloudy outlook on future earnings, in our view," said Mizuho analyst Irina Koffler. "Management previously indicated that it would consider refinancing and was more focused on its EBITDA than its EPS." Valeant's most active bonds, the 6.125% notes that mature in 2025, were last quoted at 79 cents on the dollar, according to MarketAxess. The stock has fallen 82% in the last 12 months, while the S&P 500 has gained 18%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Valeant posts wider loss for fourth quarter as revenue dips
Valeant Pharmaceuticals International Inc. shares jumped, then reversed their gains, in premarket trade Tuesday, after the company reported a fourth-quarter loss and decline in revenues, but still beat Wall Street estimates. Valeant, which was immersed in an accounting and drug pricing scandal last year, said it had a net loss of $512 million, or $1.47 a share, in the quarter, after a loss of $385 million, or $1.12 a share, in the year-earlier period. Excluding special items, the company had adjusted EPS of $1.26, ahead of the FactSet consensus of $1.20. Revenue fell to $2.4 billion from $2.7 billion, but were also ahead of the FactSet consensus of $2.3 billion. Joseph Papa, the CEO who was brought in to turn the company around, said it had improved its position in 2016. "We paid all 2017 amortizations and reduced debt by $519 million in the fourth quarter," Papa said in a statement. "We agreed to divest a number of assets, including several skincare brands, our Dendreon business and smaller international interests. The U.S. Food and Drug Administration (FDA) approved our new psoriasis treatment, SILIQ(TM), and we resubmitted our glaucoma treatment, latanoprostene bunod in February 2017." The company is expecting 2017 revenue to range from $8.9 billion to $9.1 billion. Shares are down 79% in the last 12 months, while the S&P 500 has gained 22%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Former Valeant and Philidor executives plead not guilty in fraud scheme
A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme.
UPDATED: EyeGate Pharma surges 49% on news of $4 million Valeant licensing agreement
EyeGate Pharmaceuticals Inc. shares surged nearly 50% in morning trade Tuesday after an announcement of the company's $4 million licensing agreement with Valeant Pharmaceuticals International Inc. . The deal is for exclusive, global commercial and manufacturing rights for EyeGate's EyeGate II Delivery System, which is an alternative to eye drops and ocular injections, and EGP-437 combination product, which is being developed for post-operative pain and inflammation in patients who've had ocular surgery. The deal consists of cash upfront for EyeGate, and up to $99 million in potential milestone payments and royalties on Valeant's net sales of the product, according to an EyeGate Securities and Exchange Commission filing. Valeant had previously licensed the same product, EGP-437, from EyeGate for uveitis in 2015. EyeGate reported positive results from a early/mid-stage trial in December. Valeant shares lifted 1.3% in Tuesday morning trade. Valeant shares have dropped 11.4% over the last three months, and EyeGate shares have risen 35.3%, compared with a 7.5% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Ackman boosted Chipotle holdings, pared Valeant in 4th quarter
There were no major surprises in activist hedge-fund manager Bill Ackman's fourth-quarter filing on Tuesday, which showed his Pershing Square Capital boosted its stake in burrito chain Chipotle Mexican Grill and pared its holdings of Valeant Pharmaceuticals . As previously disclosed, Ackman bought more than 2.3 million shares of Chipotle in the fourth quarter, the filing showed, bringing his stake to 2.882 million shares, or 9.96% of the company, as of Dec. 31. Pershing Square and Chipotle reached a settlement in December that gave the fund two seats on restaurant chain's board. Ackman had also disclosed in December that Pershing Square had cut its stake in Valeant by nearly 3.5 million shares to help generate a loss for tax purposes. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Valeant Pharma reiterates its FY 2016 forecast
* Valeant Pharmaceuticals International Inc - Reiterating
its full-year 2016 financial guidance, which was originally
communicated in november 2016
Williams and Ascena Retail Sink While Illumina, Valeant Jump
Williams Cos. and Ascena Retail Group take losses in U.S. trading, while Illumina and Valeant Pharmaceuticals International climb
Valeant to sell its Dendreon cancer business to China's Sanpower
Valeant Pharmaceuticals International, Inc. announced Monday night it was selling its Dendreon cancer business to Chinese conglomerate Sanpower Group Co. for $819.9 million in cash. Dandreon's only commercial product is Provenge, a treatment for prostate cancer. "With this sale, we are better aligning our product portfolio with Valeant's new operating strategy by exiting the urological oncology business, which is one of our non-core assets," Valeant CEO Joseph Papa said in a statement. Quebec-based Valeant said it would use the sale proceeds to repay loan debt, and expects the deal to close in the first half of 2017.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Valero Energy CorporationVLO
Valero Energy Partners LPVLP
Valley National BancorpVLY
Valley National BancorpVLY.WS
Valley National BancorpVLY^A
Valspar Corporation (The)VAL